Table 2.
Clinical and pathologic characteristics of the study population
| Clinical and Pathologic Characteristics | De novo GN (n = 46) | Recurrent GN (n = 77) | P value |
|---|---|---|---|
| Induction agenta | |||
| Antithymocyte globulin | 24/44 (54.6) | 46/68 (67.7) | 0.2 |
| Alemtuzumab | 5/44 (11.4) | 11/68 (16.2) | 0.6 |
| Interleukin 2 receptor antagonists | 15/44 (34.1) | 10/68 (14.7) | 0.02 |
| Total HLA mismatch (0–6)b,c | 4 (2, 5) | 3 (2, 5) | 0.2 |
| DSAd | |||
| Pre-KT DSAs | 5/36 (13.9) | 8/64 (12.5) | >0.9 |
| DSAs at time of GN discovery | 15/41 (36.6) | 10/59 (17.0) | 0.03 |
| Glomerulonephritis at index biopsy | |||
| Anti-GBM GN | 0/46 (0) | 1/77 (1) | >0.9 |
| C3 glomerulopathy | 0/46 (0) | 9/77 (12) | 0.03 |
| IgA nephropathy | 11/46 (24) | 46/77 (60) | 0.0002 |
| Membranous nephropathy | 8/46 (17) | 14/77 (18) | >0.9 |
| HCV-related GN | 4/46 (9) | 0/77 (0) | 0.02 |
| Infection related GN | 2/46 (4) | 0/77 (0) | 0.1 |
| ICGN-NOS | 21/46 (46) | 7/77 (9) | <0.0001 |
| Graft outcomes | |||
| Graft failure | 11/46 (23.9) | 21/77 (27.3) | 0.8 |
| Time from KT to graft failure, yrc | 7.9 (4.5, 12.7) | 6.8 (4.9, 12.2) | 0.9 |
| Time from GN discovery to graft failure, yrc | 1.4 (0.2, 3.5) | 1.2 (0.7, 2.6) | 0.7 |
| Last creatinine if graft has not failedc | 1.8 (1.3, 2.5) | 1.7 (1.4 2.6) | 0.8 |
Anti-GBM, anti–glomerular basement membrane; DSA, donor-specific antibody; GN, glomerulonephritis; HCV, hepatitis C virus; HLA, human leukocyte antigen; IGCN-NOS, immune complex–mediated glomerulonephritis not otherwise specified; KT, kidney transplant.
Unless otherwise noted, values are n (%).
HLA mismatch is calculated based on A, B, and DR antigens.
Induction agent is unknown in 2 subjects in the de novo group and in 9 subjects in the recurrent group. One patient in the recurrent group did not receive any induction therapy as the transplant was from a twin sibling.
HLA typing is missing in 2 patients in the de novo group and in 7 patients in the recurrent group.
Values are median (25th, 75th percentile).
DSAs at the time of transplant is missing in 10 patients in the de novo group and in 13 patients in the recurrent group. DSAs at the time of index biopsy is missing in 5 patients in the de novo group and in 18 patients in the recurrent group.